PRT, a proprietary advance treatment, is designed to prevent calcification of the Mitroflow bioprosthetic valve.
PRT can decrease phospholipid content in the pericardial tissue leading to a reduction of calcium uptake in the treated pericardial tissue.
Sorin develops technologies for cardiopulmonary bypass, cardiac rhythm management, and heart valve repair and replacement.